

Table S8: Projected gains in quality of life-adjusted survival and net cost per quality-adjusted life year with 5 years of simvastatin plus ezetimibe treatment in SHARP

	Life years gained	Quality-adjusted life years gained	Additions cost (£) of treating end-stage renal disease	Net cost (£) per quality-adjusted life-year gained
Simvastatin 20mg plus ezetimibe 10mg daily				
5-year risk of cardiovascular disease at randomization				
<10%	0.09	0.06	1,090	39,600
10% - 20%	0.11	0.08	1,400	30,500
≥20%	0.07	0.05	810	33,300
CKD stage at randomization				
3 ¹	0.15	0.13	440	13,000
4	0.15	0.11	1,370	22,400
5, not on dialysis	0.06	0.04	840	43,300
On dialysis	0.07	0.05	1,100	42,700

All outcomes and costs discounted at 3.5% per annum; ¹83% of participants in this category with chronic kidney disease (CKD) stage 3b (eGFR ≥30 to <45 ml/min/1.73m²)